



Review of the Federal Bureau of Prisons' Accounting of Drug Control Funding Fiscal Year 2024



AUDIT DIVISION

25-028

FEBRUARY 2025

REDACTED FOR PUBLIC RELEASE

Redactions were made to the full version of this report because it contained information that the Department identified as pre-decisional budget information.



EXECUTIVE SUMMARY

Review of the Federal Bureau of Prisons’ Accounting of Drug Control Funding Fiscal Year 2024

Objective

Pursuant to 21 U.S.C. § 1704(d), as implemented by the Office of National Drug Control Policy (ONDCP) Circular, National Drug Control Program Agency Compliance Reviews, dated September 9, 2021 (the Circular), the U.S. Department of Justice Federal Bureau of Prisons (FBOP) is required to submit to the Director of ONDCP a detailed accounting of all funds expended for National Drug Control Program activities during the previous fiscal year. Additionally, at least every 3 years, the Office of the Inspector General (OIG) is required by the Circular to authenticate and express a conclusion about the reliability of the detailed accounting of funds prior to FBOP management’s submission to the ONDCP.

Results in Brief

The OIG concluded that it is not aware of any material modifications that should be made to the detailed accounting of drug control funding for the year ended September 30, 2024, in order for it to be in accordance with the Circular.

Recommendations

No recommendations were provided in this report.

Audit Results

The OIG performed an attestation review of the FBOP’s detailed accounting of all funds expended for National Drug Control Program activities during the year ended September 30, 2024. The detailed accounting includes the Budget Formulation Compliance Report (BFCR), Detailed Accounting Report (DAR), and related assertions by FBOP management. The FBOP reported approximately \$3.97 billion of drug control obligations for fiscal year 2024.

The purpose of the review was to express a conclusion about whether we are aware of any material modifications that should be made to the BFCR, DAR, or related assertions in order for them to be in accordance with the requirements set forth in the Circular. We concluded that we are not aware of any such material modifications. For fiscal year 2023, the OIG also concluded that no material modifications were needed to FBOP submission to the ONDCP (OIG Audit Division Report Number 24-028).

The review was performed in accordance with the attestation standards contained in Government Auditing Standards. The procedures performed in a review vary in nature and timing from and are substantially less in extent than, an examination, the objective of which is to obtain reasonable assurance of the subject matter in order to express an opinion. Accordingly, we do not express such an opinion.

Table of Contents

Office of the Inspector General's Independent Review Report	1
Budget Formulation Compliance Report	2
Management's Assertion Statement	2
Drug Budget Resource Summary Table	3
Detailed Accounting Report	4
Management's Assertion Statement	4
Table of Drug Control Obligations and Related Disclosures	5



OFFICE OF THE INSPECTOR GENERAL'S INDEPENDENT REVIEW REPORT

Acting Director
Federal Bureau of Prisons

We have reviewed the accompanying Budget Formulation Compliance Report (BFCR) and Detailed Accounting Report (DAR) of the U.S. Department of Justice (DOJ) Federal Bureau of Prisons (FBOP) for the fiscal year ended September 30, 2024. FBOP management is responsible for the preparation of the BFCR and DAR in accordance with the Office of National Drug Control Policy (ONDCP) Circular, National Drug Control Program Agency Compliance Reviews, dated September 9, 2021 (the Circular). Our responsibility is to express a conclusion on management's assertions based on our review.

Our review was conducted in accordance with standards applicable to attestation engagements contained in Government Auditing Standards issued by the Comptroller General of the United States. Those standards require us to plan and perform the review to obtain limited assurance about whether any material modifications should be made to the BFCR, DAR, or related assertions in order for them to be in accordance with the Circular. The procedures performed in a review vary in nature and timing from and are substantially less in extent than, an examination, the objective of which is to obtain reasonable assurance about whether the BFCR, DAR, and related assertions are in accordance with the Circular, in all material respects, in order to express an opinion. Accordingly, we do not express such an opinion. Because of the limited nature of the engagement, the level of assurance obtained in a review is substantially lower than the assurance that would have been obtained had an examination been performed. We believe that the review evidence obtained is sufficient and appropriate to provide a reasonable basis for our conclusion.

We are required to be independent and to meet our other ethical responsibilities in accordance with relevant ethical requirements related to the engagement.

Based on our review, we are not aware of any material modifications that should be made to the BFCR, DAR, or related assertions for the year ended September 30, 2024, in order for them to be in accordance with the requirements set forth in the Circular.

The purpose of this report is to authenticate the BFCR and DAR as required by the Circular based on our review and is not suitable for any other purpose. This report is intended solely for the information and use of the DOJ, FBOP, and the ONDCP, and is not intended to be, and should not be, used by anyone other than the specified parties.

Kelly A. McFadden, CPA
Director, Financial Statement Audit Office
U.S. Department of Justice Office of the Inspector General
Washington, D.C.
January 17, 2025



U.S. Department of Justice
Federal Bureau of Prisons

Central Office

Washington, DC 20534

Budget Formulation Compliance Report
Management's Assertion Statement
For Fiscal Year Ended September 30, 2024

On the basis of the Federal Bureau of Prison's (FBOP) management control program, and in accordance with the guidance of the Office of National Drug Control Policy's (ONDCP) Circular, *National Drug Control Program Agency Compliance Reviews*, dated September 9, 2021, we assert that the FBOP's system of accounting, use of estimates, and systems of internal controls provide reasonable assurance that:

1. The summer drug budget submitted to ONDCP in response to ONDCP Circular, Budget Formulation, Section 9.a.(1) was submitted to ONDCP at the same time as that budget request was submitted to the Department of Justice management in accordance with 21 U.S.C § 1703(c)(1)(A).
2. The funding requests submitted to ONDCP in the Summer Drug Budget Resource Summary Table represents the funding levels in the budget submission made by the FBOP to the Department without alteration or adjustment by any official at the Department.

LONERYL BURNS

Digitally signed by LONERYL
BURNS
Date: 2025.01.17 10:58:03 -05'00'

Loneryl Burns, Acting Chief Financial Officer

January 17, 2025

Date

Department of Justice - Federal Prison System (Federal Bureau of Prisons -FBOP)

Dollars in Millions - Total Drug Resources

Resource Summary	FY 2024 Enacted	FY 2025 President's Budget	FY 2026 Spring Call
Drug Resources by Decision Unit and Function:			
<i>Decision Unit: Inmate Care and Programs</i>			
<i>Corrections</i>	\$1,545.720	\$1,456.625	
<i>Treatment</i>	\$104.247	\$209.487	
<i>Harm Reduction</i>	\$0.300	\$0.315	
Total, Decision Unit	\$1,650.267	\$1,666.427	
<i>Decision Unit: Security/Management & Administration</i>			
<i>Corrections</i>	\$1,979.182	\$1,915.256	
Total, Decision Unit	\$1,979.182	\$1,915.256	
<i>Decision Unit: Contract Confinement</i>			
<i>Corrections</i>	\$239.782	\$309.397	
<i>Treatment</i>	\$141.449	\$48.179	
Total, Decision Unit	\$381.231	\$357.576	
<i>Decision Unit: New Construction</i>			
<i>Corrections</i>	\$14.208	\$0.888	
Total, Decision Unit	\$14.208	\$0.888	
<i>Decision Unit: M&R</i>			
<i>Corrections</i>	\$65.606	\$114.647	
Total, Decision Unit	\$65.606	\$114.647	
Total Drug Funding	\$4,090.494	\$4,054.794	
Drug Resources Personnel Summary			
Total FTEs (direct only)	18,007	17,842	
Drug Resources as a Percent of Budget			
Total Agency Budget (in billions)	8.4	8.8	
Drug Resources Percentage	48.7%	46.0%	



U.S. Department of Justice
Federal Bureau of Prisons

Central Office

Washington, DC 20534

Detailed Accounting Report
Management's Assertion Statement
For Fiscal Year Ended September 30, 2024

On the basis of the Federal Bureau of Prison's (FBOP) management control program, and in accordance with the guidance of the Office of National Drug Control Policy's (ONDCP) Circular, *National Drug Control Program Agency Compliance Reviews*, dated September 9, 2021, we assert that the FBOP system of accounting, use of estimates, and systems of internal controls provide reasonable assurance that:

1. The drug control obligations are consistent with the application of the approved methodology for calculating drug control funding against the FBOP's accounting system of record for these Budget Decision Units.
2. The drug methodology used by the FBOP to calculate obligations of budgetary resources by function and budget decision unit is reasonable and accurate in all material respects.
3. The drug methodology disclosed in this statement was the actual drug methodology used to generate the Table of Drug Control Obligations.
4. All material weaknesses or other findings by independent sources, or other known weaknesses, including those identified in the Agency's Annual Statement of Assurance, which may affect the presentation of drug-related obligations have been disclosed.
5. There were no modifications to the methodology used to report drug control resources.
6. The data presented are associated with obligations against a financial plan that was revised during the fiscal year to properly reflect the changes, including ONDCP's approval for reprogrammings and transfers affecting drug-related resources in excess of \$5 million or 10 percent of a specific program.
7. FBOP did not have any ONDCP Fund Control Notices issued in FY 2024.

**LONERYL
BURNS**

Digitally signed by LONERYL
BURNS
Date: 2025.01.17 10:58:26 -05'00'

Loneryl Burns, Acting Chief
Financial Officer

January 17, 2025

Date

U.S. Department of Justice
Federal Bureau of Prisons
Detailed Accounting Report
Table of Drug Control Obligations
For Fiscal Year Ended September 30, 2024
(Dollars in Millions)

	FY 2024 Actual Obligations
Drug Resources by Budget Decision Unit and Function:	
Decision Unit #1: Inmate Care and Programs	
Treatment	\$ 96.18
Corrections	1,466.10
Harm Reduction	0.38
Total Inmate Care and Programs	\$ 1,562.66
Decision Unit #2: Security/Management and Administration	
Correction	\$ 1,972.21
Total Security/Management and Administration	\$ 1,972.21
Decision Unit #3: Contract Confinement	
Treatment	\$ 129.65
Corrections	222.78
Total Contract Confinement	\$ 352.43
Decision Unit #4: New Construction	
Corrections	\$ 1.10
Total New Construction	\$ 1.10
Decision Unit #4: Modernization and Repair	
Corrections	\$ 83.30
Total Modernization and Repair	\$ 83.30
Total Obligations	\$ 3,971.70
High-Intensity Drug Trafficking Area (HIDTA) Obligations	\$ -
Organized Crime Drug Enforcement Task Force (OCDETF) Resources	\$ -

**U.S. Department of Justice
Federal Bureau of Prisons
Detailed Accounting Report
Related Disclosures
For Fiscal Year Ended September 30, 2024**

Disclosure 1: Drug Methodology

The mission of the Federal Bureau of Prisons (FBOP) is to protect society by confining offenders in the controlled environments of prisons and community-based facilities that are safe, humane, cost-efficient, appropriately secure, and which provide work and other self-improvement opportunities to assist offenders in becoming law-abiding citizens.

The FBOP's drug resources are divided into two functions: 1) Treatment; and 2) Corrections.

Treatment Function Obligations are calculated by totaling, actual amount obligated (100%) for Drug Treatment Functions, which includes: Drug Program Screening and Assessment; Drug Abuse Education; Non-Residential Drug Abuse Treatment; Residential Drug Abuse Treatment; and Community Transitional Drug Abuse Treatment. The treatment obligations for Community Transitional Drug Treatment are captured in Contract Confinement Decision unit, where, as all other programs are included in Inmate Care and Program Decision Unit.

Correction Function Obligations are calculated by totaling, all FBOP Direct Obligations, subtracting Treatment Functions obligations from it and applying drug percentage to these obligations. Drug percentage is the percentage of inmates sentenced for drug-related crimes (44.2%).

The Harm Reduction is supported by Narcan/eligible expenses data pulled from McKesson Connect for FBOP Prime Vendor purchases. A report was received from Emergent pharmaceuticals for the small purchases from FBOP secondary vendor.

The Table of Drug Control Obligations was prepared in accordance with the Office of National Drug Control Policy (ONDCP) Circular, National Drug Control Program Agency Compliance Reviews, dated September 9, 2021. The table represents obligations incurred by the FBOP for drug control purposes. The amounts are net of all reimbursable agreements.

Data - All accounting information for the FBOP is derived from the Department of Justice (DOJ) Unified Financial Management System (UFMS).

Financial Systems - The UFMS is the DOJ financial system that provides FBOP obligation data. Obligations in this system can also be reconciled with the enacted appropriation and carryover balances.

Disclosure 2: Methodology Modifications

The overall methodology to calculate drug control obligations has not been changed from the prior year (FY 2023).

**U.S. Department of Justice
Federal Bureau of Prisons
Detailed Accounting Report
Related Disclosures
For Fiscal Year Ended September 30, 2024**

Disclosure 3: Material Weaknesses or Other Findings

In FY 2024, the independent auditors identified no material weakness in the Agency Financial Report.

Disclosure 4: Reprogrammings or Transfers

FBOP's FY 2024 obligations include all approved transfers and there was a reprogramming. (see the attached Table of Reprogrammings and Transfers). In FY 2024, there was a transfer of \$82.8 million from the FBOP's S&E funds to Health and Human Services for Public Health Service (PHS). There was also a reprogramming of \$46.3 million within the FBOP's S&E funds, of which \$20.48 million of this is related to the drug budget.

**U.S. Department of Justice
Federal Bureau of Prisons
Detailed Accounting Report
Table of Reprogrammings or Transfers
For Fiscal Year Ended September 30, 2024
(Dollars in Millions)**

Drug Resources by Budget Decision Unit and Function:	Reprogrammings	Transfers-in	Transfers-out	Total
Decision Unit #1: Inmate Care and Programs				
Corrections	\$ (10.25)	\$ 36.63	\$ (36.63)	\$ (10.25)
Total Inmate Care and Programs	\$ (10.25)	\$ 36.63	\$ (36.63)	\$ (10.25)
Decision Unit #2: Security/Management and Administration				
Corrections	\$ (10.23)	\$ -	\$ -	\$ (10.23)
Total Security/Management and Administration	\$ (10.23)	\$ -	\$ -	\$ (10.23)
Decision Unit #3: Contract Confinement				
Corrections	\$ 20.48	\$ -	\$ -	\$ 20.48
Total Contract Confinement	\$ 20.48	\$ -	\$ -	\$ 20.48
Total Funding	\$ -	\$ 36.63	\$ (36.63)	\$ -
High-Intensity Drug Trafficking Area (HIDTA) Transfer	\$ -	\$ -	\$ -	\$ -
Organized Crime Drug Enforcement Task Force (OCDETF)	\$ -	\$ -	\$ -	\$ -